





Supplemental Figure 1. Identification and characterization of new chemical entities targeting APE1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). Kelley, Wikel, Guo, Pollok, Bailey, Wireman, Fishel, and Vasko. J Pharmacology Experimental Toxicology



Supplemental Figure 2. Identification and characterization of new chemical entities targeting APE1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). Kelley, Wikel, Guo, Pollok, Bailey, Wireman, Fishel, and Vasko. J Pharmacology Experimental Toxicology

	Reporter Transactivation Assay IC50 uM	Tumor Cell killing IC50 uM	Increase in APE1 DNA repair activity ⁶	t _{1/2} hrs ⁴	P450 Metabolism t _{1/2} min ⁵
E3330	45 ¹	26 ¹	25-50 uM ¹	3.6	20
APX2007	7	3.6 – 6.2 ²	ND	2.9	
APX2009	7	3 – 6 ² 2.5 – 5.0 ³	0.125 uM	25.8	173
APX2032	7	4 – 25 ²	ND	2.8	
APX2009 increase in activity vs. E3330 (fold)	6.4	4.3 – 8.7	200	7.2	8.7

Supplemental Figure 3. Identification and characterization of new chemical entities targeting APE1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). Kelley, Wikel, Guo, Pollok, Bailey, Wireman, Fishel, and Vasko. J Pharmacology Experimental Toxicology

Avg IC50 values for IMR32 cells
p53wt, MYCN amplified

Compound	IC50 (μM)	SEM
E3330	25.14	1.38
APX2007	3.58	1.38
APX2009	3.00	0.41
APX2032	2.47	0.27

Avg IC50 values for SK-N-SH cells
p53wt, MYCN non-amplified

Compound	IC50 (μM)	SEM
E3330	27.30	0.97
APX2007	6.23	1.1
APX2009	5.96	0.57
APX2032	4.37	0.22

Supplemental Figure 4. Identification and characterization of new chemical entities targeting APE1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). Kelley, Wikel, Guo, Pollok, Bailey, Wireman, Fishel, and Vasko. J Pharmacology Experimental Toxicology

